Cadrenal Therapeutics, INC DEF 14A proxy statements

Cadrenal Therapeutics, Inc. has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, auditor ratification, equity plan amendments, and warrant exercise approval.

Cadrenal Therapeutics, Inc. has filed definitive additional materials outlining proposals for its upcoming stockholder meeting, including director election and auditor ratification.

Cadrenal Therapeutics, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on September 24, 2025, to vote on the election of a Class III director and the ratification of its independent registered public accounting firm.

Cardenal Therapeutics is asking stockholders to vote on key proposals including a reverse stock split, an increase in authorized shares, and amendments to their equity incentive plan at the upcoming annual meeting.

Cadrenal Therapeutics is asking stockholders to approve a reverse stock split, an increase in authorized shares, and an amendment to its equity incentive plan at the upcoming annual meeting.